OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
Not Applicable
Recruiting
- Conditions
- Ovarian Neoplasm EpithelialFallopian Tube NeoplasmsOvarian Endometrioid CarcinomaHigh-grade Serous Ovarian Carcinoma (HGSOC)
- Interventions
- Other: Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Swiss GO Trial Group
- Target Recruit Count
- 60
- Registration Number
- NCT06466382
- Locations
- 🇨🇭
Kantonsspital Baden AG, Baden, Aargau, Switzerland
🇨🇭HOCH Health Ostschweiz Kantonsspital St.Gallen, St Gallen, Saint Gallen, Switzerland
🇨🇭Thurgau AG Frauenfeld / Münsterlingen, Frauenfeld, Thurgau, Switzerland
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Phase 3
Recruiting
- Conditions
- Ovarian Neoplasm EpithelialLow-grade Serous Ovarian Carcinoma (LGSOC)Ovarian Endometrioid CarcinomaFallopian Tube NeoplasmsHigh-grade Serous Ovarian Carcinoma (HGSOC)Peritoneal Neoplasms
- Interventions
- Other: Placebo
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Swiss GO Trial Group
- Target Recruit Count
- 540
- Registration Number
- NCT04111978
- Locations
- 🇨🇭
Universitätsklinik für Medizinische Onkologie, Inselspital, Bern, Switzerland
🇨🇭Oncology Institute of Southern Switzerland (IOSI)-Ente Ospedaliero Cantonale (EOC), Bellinzona, Ticino, Switzerland
🇦🇹Krankenhaus der Barmherzigen Brüder Graz, Graz, Austria
© Copyright 2025. All Rights Reserved by MedPath